Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double-blind, placebo-controlled, with escitalopram (10 mg/day with potential blinded adjustment to 20 mg/day) as validator, 3-arm parallel groups, international multicenter study.

Trial Profile

Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double-blind, placebo-controlled, with escitalopram (10 mg/day with potential blinded adjustment to 20 mg/day) as validator, 3-arm parallel groups, international multicenter study.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs Agomelatine (Primary) ; Escitalopram
  • Indications Generalised anxiety disorder
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2012 Results reported at the 28th International Congress of Cellegium Internationale Neuro-Psychopharmacologicum.
    • 18 Aug 2011 Additional trial locations identified as reported by ISRCTN: Current Controlled Trials.
    • 14 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top